Seminars in Nephrology
Volume 25, Issue 6 , Pages 372-378 , November 2005

Heart Disease in Diabetic Patients

  • Robert D. Toto

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Robert D. Toto, MD, Professor of Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-8856.

References 

  1. Damsgaard EM , Froland A , Jorgensen OD , et al.   Eight to nine year mortality in known non-insulin dependent diabetics and controls . Kidney Int . 1992;41:731–735
  2. Klein BE , Klein R , McBride PE , et al.   Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes (Wisconsin epidemiologic study of diabetic retinopathy) . Arch Intern Med . 2004;164:1917–1924
  3. Borch-Johnsen K , Andersen K , Deckert T . The impact of proteinuria on the relative mortality in patients with type I diabetes mellitus . Diabetologia . 1985;28:590–596
  4. Giansanti R , Rabini RA , Romagnoli F , et al.   Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors (A study on a middle-aged and elderly population) . Arch Gerontol Geriatr . 1999;29:175–181
  5. Almdal T , Scharling H , Jensen JS , et al.   The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death (a population-based study of 13,000 men and women with 20 years of follow-up) . Arch Intern Med . 2004;164:1422–1426
  6. Marchesini G , Forlani G , Cerrelli F , et al.   WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes . Diabet Med . 2004;21:383–387
  7. Lim HS , MacFadyen RJ , Lip GY . Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart . Arch Intern Med . 2004;164:1737–1748
  8. Colhoun HM , Betteridge DJ , Durrington PN , et al.   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) (Multicentre randomised placebo-controlled trial) . Lancet . 2004;364:685–696
  9. Wilson Tang WH , Maroo A , Young JB . Ischemic heart disease and congestive heart failure in diabetic patients . Med Clin North Am . 2004;88:1037–1061
  10. Danielsen R , Nordrehaug JE , Vik-Mo H . Left ventricular diastolic function in young long-term type 1 (insulin-dependent) diabetic men during exercise assessed by digitized echocardiography . Eur Heart J . 1988;9:395–402
  11. Borow KM , Jaspan JB , Williams KA , et al.   Myocardial mechanics in young adult patients with diabetes mellitus (Effects of altered load, inotropic state and dynamic exercise) . J Am Coll Cardiol . 1990;15:1508–1517
  12. Unger T , Ganten D , Lang R , et al.   Is tissue converting enzyme inhibitor a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneous hypertensive rats . J Cardiovasc Pharmacol . 1984;6:872–880
  13. Unger RH , Orci L . Lipoapoptosis (Its mechanism and its diseases) . Biochim Biophys Acta . 2004;1585:202–212
  14. Monti LD , Landoni C , Setola E , et al.   Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in type 2 diabetic patients . Am J Physiol . 2004;287:H1225–H1231
  15. Lurbe E , Redon J , Kesani A , et al.   Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes . N Engl J Med . 2002;347:797–805
  16. Quinones M , Hernandez-Pampaloni M , Schelbert H . Coronary vasomotor abnormalities in insulin-resistant individuals . Ann Intern Med . 2004;140:700–708
  17. Bakris GL , Williams M , Dworkin L , et al.  National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group   Preserving renal function in adults with hypertension and diabetes (A consensus approach) . Am J Kidney Dis . 2000;36:646–661
  18. El Atat F , McFarlane SI , Sowers JR . Diabetes, hypertension, and cardiovascular derangements (Pathophysiology and management) . Curr Hypertens Rep . 2004;6:215–223
  19. Wachtell K , Ibsen H , Olsen MH , et al.   Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy (The LIFE study) . Ann Intern Med . 2003;139:901–906
  20. Saito I , Folsom AR , Brancati FL , et al.   Nontraditional risk factors for coronary heart disease incidence among persons with diabetes (The Atherosclerosis Risk in Communities (ARIC) study) . Ann Intern Med . 2000;133:81–91
  21. McClellan WM , Flanders WD , Langston RD , et al.   Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals (A population-based study) . J Am Soc Nephrol . 2002;13:1928–1936
  22. Silverberg DS , Wexler D , Blum M , et al.   The interaction between heart failure, renal failure and anemia—the cardio-renal anemia syndrome . Blood Purif . 2004;22:277–284
  23. Silverberg DS , Wexler D , Blum M , et al.   The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations . J Am Coll Cardiol . 2000;35:1737–1744
  24. Levin A . Anaemia in the patient with renal insufficiency (Documenting the impact and reviewing treatment strategies) . Nephrol Dial Transplant . 1999;14:292–295
  25. Levin A . Anemia and left ventricular hypertrophy in chronic kidney disease populations (A review of the current state of knowledge) . Kidney Int . 2002;61(suppl):35–38
  26. London GM , Pannier B , Guerin AP , et al.   Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis (Follow-up of an interventional study) . J Am Soc Nephrol . 2001;12:2759–2767
  27. London GM , Guerin AP , Marchais SJ . Pathophysiology of left ventricular hypertrophy in dialysis patients . Blood Purif . 1994;12:277–283
  28. London GM , Fabiani F , Marchais SJ , et al.   Uremic cardiomyopathy (An inadequate left ventricular hypertrophy) . Kidney Int . 1987;31:973–980
  29. Haffner SM , Alexander CM , Cook TJ , et al.   Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels (Subgroup analyses in the Scandinavian Simvastatin Survival Study) . Arch Intern Med . 1999;159:2661–2667
  30. Kazumi T , Yoshino G , Ohki A , et al.  Hyogo Simvastatin Study Group   Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors . Horm Metab Res . 1995;27:239–243
  31. MRC/BHF Heart Protection Study: Cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial . Lancet . 2002;360:7–22
  32. Sever PS , Dahlof B , Poulter NR , et al.   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA) (A multicentre randomised controlled trial) . Lancet . 2003;361:1149–1158
  33. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38 . BMJ . 1998;317:703–713
  34. Adler AI , Stratton IM , Neil HA , et al.   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36) (Prospective observational study) . BMJ . 2000;321:412–419
  35. HOPE Trial Investigators Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus (Results of the HOPE study and MICRO-HOPE substudy) . Lancet . 2000;355:253–259
  36. Dahlof B , Devereux RB , Kjeldsen SE , et al.   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (A randomised trial against atenolol) . Lancet . 2002;359:995–1003
  37. Gaede P , Vedel P , Larsen N , et al.   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes . N Engl J Med . 2003;348:383–393
  38. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  39. Wanner C , Krane V , Ruf G , et al.  Die Deutsche Diabetes Dialyse Studie Investigators   Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis . Kidney Int Suppl . 1999;71:S222–S226
  40. Baigent C , Landry M . Study of Heart and Renal Protection (SHARP) . Kidney Int . 2003;63(suppl):S207–S210
  41. Mix TC , Brenner RM , Cooper ME , et al.   Rationale—Trial to reduce cardiovascular events with Aranesp Therapy (TREAT) (evolving the management of cardiovascular risk in patients with chronic kidney disease) . AM Heart J . 2005;149(3):408–413
  42. Bakris GL , Weir MR , Secic M , et al.   Differential effects of calcium antagonist subclasses on markers of nephropathy progression . Kidney Int . 2004;65:1991–2002
  43. Smith AC , Toto R , Bakris GL . Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy . Kidney Int . 1998;54:889–896
  44. Pitt B , Remme W , Zannad F , et al.   Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction . N Engl J Med . 2003;348:1309–1321
  45. Pitt B , Zannad F , Remme WJ , et al.  Randomized Aldactone Evaluation Study Investigators   The effect of spironolactone on morbidity and mortality in patients with severe heart failure . N Engl J Med . 1999;341:709–717
  46. Juurlink DN , Mamdani MM , Lee DS , et al.   Rates of hyperkalemia after publication of the randomized aldactone evaluation study . N Engl J Med . 2004;351:543–551
  47. Raskin P . Diabetes control and complications trial (Implications for the treatment of diabetes mellitus) . Texas: The University of Texas SW Medical Center, Medical Grand Rounds, Dallas, Texas; 1994;
  48. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus . N Engl J Med . 1993;329:977–986
  49. UKPDS Glucose Investigators UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . Lancet . 1998;352:837–853
  50. American Diabetes Association . Standards of medical care for patients with diabetes mellitus . Diabetes Care . 2003;26:33S–35S
  51. Grundy SM , Cleeman JI , Merz CN , et al.   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines . Circulation . 2004;110:227–239
  52. Corradi L , Zoppi A , Tettamanti F , et al.   Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus . J Hypertens . 1993;11:S190–S191
  53. Gall MA , Hougaard P , Borch-Johnsen K , et al.   Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus (Prospective, observational study) . BMJ . 1997;314:783–788
  54. Hovind P , Rossing P , Tarnow L , et al.   Smoking and progression of diabetic nephropathy in type 1 diabetes . Diabetes Care . 2003;26:911–916
  55. Sawicki PT , Didjurgeit U , Muhlhauser I . Smoking is associated with progression of diabetic nephropathy . Diabetes Care . 1994;17:126–131

PII: S0270-9295(05)00100-2

doi: 10.1016/j.semnephrol.2005.05.005

Seminars in Nephrology
Volume 25, Issue 6 , Pages 372-378 , November 2005

Article Tools